Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
14.80
-0.11 (-0.74%)
At close: Apr 24, 2026, 4:00 PM EDT
14.52
-0.28 (-1.89%)
After-hours: Apr 24, 2026, 7:55 PM EDT
Adlai Nortye Revenue
In the year 2025, Adlai Nortye had annual revenue of $5.00M. Adlai Nortye had revenue of $5.00M in the half year ending December 31, 2025.
Revenue (ttm)
$5.00M
Revenue Growth
n/a
P/S Ratio
118.40
Revenue / Employee
$45,872
Employees
109
Market Cap
592.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 45.73M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 311.71M |
| Arvinas | 262.60M |
| Gyre Therapeutics | 116.59M |
| Zevra Therapeutics | 106.47M |
| Aclaris Therapeutics | 7.83M |
| Prime Medicine | 4.63M |
| ProKidney | 893.00K |
ANL News
- 9 days ago - Adlai Nortye Announces $150.0 Million Private Placement Equity Financing - GlobeNewsWire
- 2 months ago - Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations - GlobeNewsWire
- 2 months ago - Adlai Nortye Announces $140.0 Million Private Placement Equity Financing - GlobeNewsWire
- 4 months ago - Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - GlobeNewsWire
- 6 months ago - Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 2 years ago - Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 - GlobeNewsWire
- 2 years ago - Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy - GlobeNewsWire
- 2 years ago - Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development - GlobeNewsWire